XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.21.1

License rights and other intangible assets, net | 3 Months Ended
--- | ---
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
License rights and other intangible assets, net |
6. | License rights and other intangible assets, net
The following provides information about our license rights and other intangible assets, net (in thousands):
|  | March 31, 2021 |  |  | December 31, 2020 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net |
Intangible assets subject to amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License rights agreement |  | $ | 40,000 |  |  | $ | 4,559 |  |  | $ | 35,441 |  |  | $ | 40,000 |  |  | $ | 3,803 |  |  | $ | 36,197 |
Hormone therapy drug patents |  |  | 4,181 |  |  |  | 818 |  |  |  | 3,363 |  |  |  | 4,045 |  |  |  | 748 |  |  |  | 3,297 |
Hormone therapy drug patents applied and pending approval |  |  | 1,857 |  |  |  | — |  |  |  | 1,857 |  |  |  | 1,628 |  |  |  | — |  |  |  | 1,628 |
|  |  | 46,038 |  |  |  | 5,377 |  |  |  | 40,661 |  |  |  | 45,673 |  |  |  | 4,551 |  |  |  | 41,122 |
Intangible assets not subject to amortization Trademarks/trade name rights |  |  | 333 |  |  |  | — |  |  |  | 333 |  |  |  | 323 |  |  |  | — |  |  |  | 323 |
|  | $ | 46,371 |  |  | $ | 5,377 |  |  | $ | 40,994 |  |  | $ | 45,996 |  |  | $ | 4,551 |  |  | $ | 41,445 |
During the three months ended March 31, 2021 and 2020, we recorded $ 756 thousand and $ 746 thousand, respectively, in amortization expense related to an exclusive license agreement (the “Population Council License Agreement”) with Population Council to commercially manufacture and sell ANNOVERA in the U.S., which was recorded as a component of cost of sales. As of March 31, 2021 and December 31, 2020, respectively, we had a total of 79 patents, of which 40 were domestic, and a total of 77 patents, of which 38 were domestic. We recorded $ 70 thousand and $ 63 thousand of amortization expense related to patents for the three months ended March 31, 2021 and 2020, respectively. We use a combination of qualitative and quantitative factors to assess intangible assets for impairment. As a result of performing these assessments, we determined that no impairment existed as of March 31, 2021 and, therefore, recorded no write-downs to any of our intangible assets.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration